Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
capecitabine + everolimus + lapatinib
- Development stage
- Unknown
- Lead developer
- TRIO-US
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A novel triplet combination therapy consisting of capecitabine, everolimus, and lapatinib. This combination targets HER2-positive breast cancer with central nervous system (CNS) metastases through multiple mechanisms: lapatinib inhibits EGFR and HER2 tyrosine kinases, everolimus selectively inhibits the mammalian target of rapamycin (mTOR), and capecitabine is converted to 5-fluorouracil in tumor tissue to inhibit DNA synthesis.
02
Targets
TS (Thymidylate synthase)Mechanistic target of rapamycin complex 1EGFR T790M (Epidermal growth factor receptor T790M mutant)ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on capecitabine + everolimus + lapatinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on capecitabine + everolimus + lapatinib.